KRYS - CIK 0001711279
Krystal Biotech, Inc. (KRYS) reported net income of $204.83M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | $204.83M | +129.7% |
| FY 2024 | $89.16M | +715.6% |
| FY 2023 | $10.93M | +107.8% |
| FY 2022 | -$139.97M | -101.2% |
| FY 2021 | -$69.57M | -116.3% |
| FY 2020 | -$32.17M | -68.5% |
| FY 2019 | -$19.09M | -75.3% |
| FY 2018 | -$10.89M | -37.5% |
| FY 2017 |
Krystal Biotech, Inc. (KRYS) reported net income of $204.83M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2016 and fiscal 2025, Krystal Biotech, Inc.'s net income grew from -$1.15M to $204.83M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$7.92M |
| -588.7% |
| FY 2016 | -$1.15M | - |